| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 7.77B | 8.03B | 2.12B | 31.37B | 21.98B | 9.16B |
| Depreciation and amortization | 6.59B | 7.01B | 6.29B | 5.06B | 5.19B | 4.68B |
| Stock-based compensation | 799.00M | 877.00M | 525.00M | 872.00M | 1.18B | 755.00M |
| Cash from operations | 11.70B | 12.74B | 8.70B | 29.27B | 32.58B | 14.40B |
| Capital expenditure | -2.63B | -2.91B | -3.91B | -3.24B | -2.71B | -2.23B |
| Free cash flow | 9.07B | 9.84B | 4.79B | 26.03B | 29.87B | 12.18B |
| Acquisitions | -6.93B | 0 | -43.43B | -23.00B | 0 | 0 |
| Cash from investing | -1.35B | 2.65B | -32.28B | -15.78B | -22.55B | -4.27B |
| Share buybacks | 0 | 0 | -2.00B | 0 | 0 | |
| Net debt issued | 2.92B | -2.25B | 28.26B | -3.30B | -1.01B | 1.22B |
| Cash from financing | -10.30B | -17.14B | 26.07B | -14.83B | -9.82B | -9.65B |
| Net change in cash | 91.00M | -1.81B | 2.45B | -1.51B | 159.00M | 475.00M |
From Pfizer's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.